European Penny Stocks To Watch In July 2025

The European stock market has shown mixed returns recently, with the pan-European STOXX Europe 600 Index remaining relatively flat and individual country indices experiencing varied performance. Amid these conditions, investors often seek opportunities in lesser-known corners of the market, such as penny stocks. While the term "penny stocks" may seem outdated, these investments can still offer significant growth potential when backed by robust financial health and solid fundamentals.

Top 10 Penny Stocks In Europe

Click here to see the full list of 324 stocks from our European Penny Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

Arterra Bioscience (BIT:ARBS)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Arterra Bioscience S.p.A. is a research-based biotech company focused on the research and development of various ingredients and natural solutions, with a market cap of €17.18 million.

Operations: The company generates revenue from its Specialty Chemicals segment, amounting to €4.17 million.

Market Cap: €17.18M

Arterra Bioscience, with a market cap of €17.18 million, shows promising traits for investors interested in penny stocks. Its debt is well-covered by operating cash flow, and short-term assets exceed liabilities significantly. Despite having low revenue from its Specialty Chemicals segment (€4.17 million), the company has demonstrated consistent earnings growth over five years at 8.7% annually, with an acceleration to 24.2% last year. The board and management team are experienced, though return on equity remains low at 11.7%. Recent financials indicate stable performance with revenues increasing to €5.27 million in 2024 from €4.95 million the previous year.

• Click here to discover the nuances of Arterra Bioscience with our detailed analytical financial health report.
• Explore historical data to track Arterra Bioscience's performance over time in our past results report.

Freelance.com (ENXTPA:ALFRE)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Freelance.com SA facilitates connections between companies and intellectual service providers across several countries, including France, Germany, and the United Kingdom, with a market cap of €129.96 million.

Operations: The company generates its revenue primarily from business services, amounting to €1.05 billion.

Market Cap: €129.96M

Freelance.com, with a market cap of €129.96 million, stands out in the penny stock realm due to its robust revenue generation of €1.05 billion primarily from business services across Europe. The company has shown impressive earnings growth over the past year at 23.9%, surpassing industry averages, although its return on equity remains modest at 10.8%. While debt levels have increased over five years, they remain satisfactorily covered by assets and interest payments are well-managed by EBIT. Recent announcements highlight stable financial performance with net income rising to €18 million for 2024 and an upcoming dividend of €0.08 per share.

• Dive into the specifics of Freelance.com here with our thorough balance sheet health report.
• Gain insights into Freelance.com's outlook and expected performance with our report on the company's earnings estimates.

Valbiotis (ENXTPA:ALVAL)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Valbiotis SA focuses on researching and developing dietary supplements aimed at preventing metabolic and cardiovascular diseases in France, with a market cap of €13.69 million.

Operations: The company's revenue is primarily derived from its Vitamins & Nutrition Products segment, totaling €0.18 million.

Market Cap: €13.69M

Valbiotis, a French biotech company with a market cap of €13.69 million, is pre-revenue with earnings primarily from its Vitamins & Nutrition Products segment (€0.18 million). Despite being unprofitable and having increased debt levels over the past five years, Valbiotis maintains sufficient short-term assets to cover liabilities and has more cash than total debt. Recent developments include launching ValbiotisPRO® Cardio-circulation in France and expanding its product range with scientifically-backed natural health solutions. A recent rights offering aims to raise €6.85 million to support ongoing operations and product development initiatives, reflecting strategic growth efforts amidst high share price volatility.

• Click here and access our complete financial health analysis report to understand the dynamics of Valbiotis.
• Assess Valbiotis' future earnings estimates with our detailed growth reports.

Make It Happen

• Dive into all 324 of the European Penny Stocks we have identified here.
• Ready To Venture Into Other Investment Styles? We've found 16 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com